CFO
CORT icon

CVA Family Office’s Corcept Therapeutics CORT Stock Holding History

CVA Family Office’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$174 Sell
2
-65
-97% -$3.92K ﹤0.01% 1774
2026
Q1 		$2.7K Buy
67
+2
+3% +$75 ﹤0.01% 1439
2025
Q4 		$2.26K Hold
65
– – ﹤0.01% 973
2025
Q3 		$5.4K Hold
65
– – ﹤0.01% 888
2025
Q2 		$4.77K Hold
65
– – ﹤0.01% 896
2025
Q1 		$7.42K Hold
65
– – ﹤0.01% 841
2024
Q4 		$3.27K Hold
65
– – ﹤0.01% 928
2024
Q3 		$3.01K Hold
65
– – ﹤0.01% 923
2024
Q2 		$2.11K Buy
+65
New +$1.78K ﹤0.01% 950

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CVA Family Office's CORT Position: Q2 2026 in Review

CVA Family Office reduced its Corcept Therapeutics (CORT) stake by 97% in Q2 2026, selling an estimated $3.92K and leaving 2 shares worth $174. The position accounts for ﹤0.01% of the portfolio, ranked #1774.

CVA Family Office first reported a position in CORT in Q2 2024 and has held it in 9 quarters since. The position peaked at $7.42K in Q1 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • CVA Family Office held 2 shares of Corcept Therapeutics worth $174 as of Q2 2026.
  • CVA Family Office sold 65 Corcept Therapeutics shares in Q2 2026, an estimated $3.92K.
  • Corcept Therapeutics made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #1774 holding.
  • CVA Family Office first reported a position in Corcept Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • CVA Family Office's Corcept Therapeutics position peaked at $7.42K in Q1 2025.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.